SMAD-signaling inhibition : potential for developing newer treatments for corneal fibrosis [abstract]

dc.contributor.advisor	Mohan, Rajiv R.	eng
dc.contributor.author	Gupta, Rangan, 1978-	eng
dc.contributor.author	Tandon, Ashish	eng
dc.contributor.author	Tovey, Jonathan	eng
dc.contributor.author	Sharma, Ajay	eng
dc.contributor.corporatename	University of Missouri--Columbia. School of Medicine	eng
dc.contributor.meetingname	Health Sciences Research Day (2010 : University of Missouri)	eng
dc.date.issued	2010	eng
dc.description.abstract	Transforming growth factor [beta] (TGFb) is known to cause fibrosis in the cornea following injury and/or infection. Effective reduction in corneal fibrosis has been reported by inhibiting TGFb activity. However, associated molecular mechanism is still unknown. The aim of study was to test the hypothesis that the alteration in SMAD signaling is a novel approach for treating corneal fibrosis using an established in vitro model.	eng
dc.format.extent	1 page	eng
dc.identifier.uri	http://hdl.handle.net/10355/9414
dc.language	English	eng
dc.relation.ispartofcommunity	University of Missouri--Columbia. Health Sciences Research Day	eng
dc.rights	OpenAccess.	eng
dc.rights.license	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.	eng
dc.subject	myofibroblasts	eng
dc.subject	anti-fibrotic therapies	eng
dc.subject.FAST	Eye -- Diseases	eng
dc.subject.FAST	Transforming growth factors-beta	eng
dc.subject.FAST	Fibrosis	eng
dc.title	SMAD-signaling inhibition : potential for developing newer treatments for corneal fibrosis [abstract]	eng
dc.type	Abstract	eng

2010 Health Sciences Research Day (MU)
Poster presentation abstracts for 2010 Health Sciences Research Day.